NYMXF | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 20%

Performance

5 Days

0 0%

1 Month

-31.03%

3 Months

4.93%

6 Months

-9.09%

1 Year

-9.09%

2 Year

-9.09%

Key data

Stock price

$0.10

P/E Ratio

N/A

DAY RANGE

$0.09 - $0.10

EPS

N/A

52 WEEK RANGE

$0.07 - $0.15

52 WEEK CHANGE

-$9.09

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$25,934

AVERAGE 30 VOLUME

$21,935

Company detail

CEO: Paul Averback
Region: US
Website: nymox.com
Employees: 3
IPO year: 2023

Issue type:
Market: OTCM
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

Nymox Pharmaceutical Corporation engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

NYMXF - NYMOX PHARMACEUTICAL CORP